Meccellis Biotech
A worldwide company recognised in the field of biomaterial. Meccellis Biotech is born from the meeting of a Biological Engineering and two engineers specialized in surgery Affairs. These three experts have combined their experience and know-how to make of Meccellis Biotech a company expert in Tissue and Cell Engineering with a diversified offer for multiple surgical specialties. After 10 years of marketing, Meccellis Biotech is now present in 22 countries. The passion and professionalism of its teams have made of Meccellis Biotech, a reference company in biomaterials.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Medical Equipment
- Market Focus:
- Globally (various continents)
About Us
Meccellis Biotech is the first French company of biological implants based on acellular dermis, born from the aspiration to better serve surgeons and patients and to correspond to their daily needs.
Our biological implants are the results of a tissue and cellular engineering and continuous dialogue with surgeons.
The constant awareness of the medical world is the foundation of our values, it guarantees the quality of our products.
Tomorrow takes place todayMake accessible high technology is at the heart of our objectives.
Through the collaboration with scientific commitees and surgical teams that trust us, we identify unmet clinical needs and offer the adapted solution by type of surgery.
Today our implants are used for the General surgery and also for Breast reconstruction.
Our product range will be soon available for new clinical indications.
Research and Development
EXCLUSIVE R&D PROCESS
New abdominal wall formation from a biological implant is a multi-step mechanism. During this process, metalloproteinases (MMps) which are involved in physiological wound healing allows the implant integration. MMPs are proteolytic enzymes synthesized during non-pathologic extracellular matrix (ECM) remodelling in order to degrade specifically ECM molecules. They can also remodel biological implants to create a physiological abdominal wall. However, an abnormal high level of MMPs can induce an unwanted fast implant degradation. In addition, on septic sites, proteases are produced by bacteria that further degrade ECM molecules, interfering with the physiological implant integration. Thus, the MMPs level plays a crucial role in the integration of the implant. To address this issue, we are working with a scientific committee to develop next generation of biomaterials that will help to treat complex pathologies where tissue and cellular engineering could meet unsatisfied medical needs.
The Scientific Committee of Meccellis Biotech is composed exclusively of surgeons’ specialists involved in our R&D programs.
Meccellis Biotech has also established a partnership with companies expert in collagen and absorbable biopolymers to achieve its R&D projects.